# Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

> **NCT00670982** · PHASE2 · COMPLETED · sponsor: **Harold J. Burstein, MD, PhD** · enrollment: 29 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** vinorelbine
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00670982
- **Lead sponsor:** Harold J. Burstein, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670982, "Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00670982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*